Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 15/20 | 1.00 |
| ▸ | PLK1 | P53350 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 6/20 | 0.79 |
| ▸ | CDK1 | P06493 | 5/20 | 0.79 |
| ▸ | CDK7 | P50613 | 5/20 | 0.79 |
| ▸ | CDK9 | P50750 | 5/20 | 0.79 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.79 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.76 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589637 | 0.89 | CDK2 (0.82) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL5052445 | 0.87 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL6160035 | 0.87 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL6157084 | 0.87 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL6157812 | 0.87 | CDK2 (0.79) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL2075942 | 0.87 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL6158693 | 0.87 | CDK2 (0.79) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL2284091 | 0.86 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL4312523 | 0.86 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK1 | |
| SCHEMBL4802162 | 0.86 | CDK2 (0.76) | CDK2CDK4PLK1AURKACDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132484-A1 | Method for Identifying Inhibitors Using a Homology Model of Polo-Like Kinase 1 | CYCLACEL LIMITED (GB) | 2008-06-05 | — | — | US | claimed |
| CN-100355751-C | 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders | CYCLACEL LTD (GB) | 2007-12-19 | — | — | CN | claimed |
| EP-1683056-A2 | METHOD FOR IDENTIFYING INHIBITORS USING A HOMOLOGY MODEL OF POLO-LIKE KINASE 1 | Cyclacel Limited (GB) | 2006-07-26 | — | — | EP | claimed |
| US-20050288307-A1 | Anti-viral compounds | CYCLACEL LIMITED (GB) | 2005-12-29 | — | — | US | claimed |
| EP-1581231-A1 | ANTI-VIRAL COMPOUNDS | Cyclacel Limited (GB) | 2005-10-05 | — | — | EP | claimed |
| WO-2005047526-A2 | METHOD FOR IDENTIFYING INHIBITORS USING A HOMOLOGY MODEL OF POLO-LIKE KINASE 1 | CYCLACEL LIMITED (GB) | 2005-05-26 | — | — | WO | claimed |
| WO-2004043467-A1 | ANTI-VIRAL COMPOUNDS | CYCLACEL LIMITED (GB) | 2004-05-27 | — | — | WO | claimed |
| US-20030149057-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2003-08-07 | — | — | US | claimed |
| CN-1420884-A | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative diseases | CYCLACEL LTD (GB) | 2003-05-28 | — | — | CN | claimed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | claimed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | claimed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | claimed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | claimed |
| US-20110195968-A1 | THIAZOLES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2011-08-11 | — | — | US | disclosed |
| US-20090030024-A1 | THIAZOLES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20080132484-A1 | Method for Identifying Inhibitors Using a Homology Model of Polo-Like Kinase 1 | CYCLACEL LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-6531479-B2 | Anticancer agents, skin disorders | CYCLACEL LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1274705-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2003-01-15 | — | — | EP | disclosed |
| US-20020019404-A1 | Anti-cancer compounds | CYCLACEL LIMITED (GB) | 2002-02-14 | — | — | US | disclosed |
| WO-2001072745-A1 | 2-SUBSTITUTED 4-HETEROARYL-PYRIMIDINES AND THEIR USE IN THE TREATMETN OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019404-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CDK2 2/4885CDK4 3/4885PLK1 53/4885 |
| US-20030149057-A1 | Anti-cancer compounds | CDK3, CDK2, CDK4 | CDK2 2/4885CDK4 3/4885PLK1 53/4885 |
| US-20090030024-A1 | THIAZOLES AS FUNGICIDES | CYP4X1, CYP4Z1, RDX | CDK2 2065/4885CDK4 776/4885PLK1 4801/4885 |
| US-20110195968-A1 | THIAZOLES AS FUNGICIDES | CYP4X1, CYP4Z1, CYP3A4 | CDK2 2144/4885CDK4 818/4885PLK1 4819/4885 |
| US-20080132484-A1 | Method for Identifying Inhibitors Using a Homology Model of Polo-Like Kinase 1 | PLK2, PLK4, PLK1 | CDK2 548/4885CDK4 524/4885PLK1 3/4885 |
| US-20050288307-A1 | Anti-viral compounds | MAVS, HAVCR2, EIF2AK2 | CDK2 205/4885CDK4 477/4885PLK1 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.